The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...
With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is hindered by its production ...
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...